Redx Pharma

Redx Pharma is a focused, AIM-listed biotech with a mission to translate innovative science into novel treatments for fibrosis and cancer. The company has achieved key milestones, including Fast Track designation for its lead GI-restricted ROCK inhibitor (RXC008) and reporting Phase 2a data for its systemic ROCK2 inhibitor, zelasudil (RXC007). Its strategy centers on a proprietary drug discovery platform, a balanced pipeline of proprietary and partnered assets, and a clear path to value inflection through clinical data readouts and strategic partnerships.

An integrated medicinal chemistry and drug discovery platform specialized in designing selective and tissue-targeted small molecule inhibitors against validated pathways in fibrosis and cancer, such as ROCK, DDR, and Wnt.

Redx competes in fibrosis with large pharma and other biotechs, differentiating via selective (ROCK2) and tissue-restricted (GI) ROCK inhibitors aimed at better tolerability. In partnered oncology, it leverages major players' resources to compete in crowded but high-value target spaces (Wnt, RAF, KRAS).